In a meta-analysis published in
Introduction
Hypertension affects from 20% to 30% of the world's population and is a major cardiovascular risk factor ( 1 , 2 ) . The relation between cardiovascular risk and blood pressure is continuous, consistent across age groups, present in all ethnic groups, and independent of other risk factors ( 1 , 2 ) . The ultimate goal of any blood pressure-lowering therapy is to reverse the risk associated with an elevated blood pressure and to prevent the cardiovascular complications associated with hypertension ( 3 , 4 ) .
Placebo-controlled clinical trials have proven that blood pressure lowering with various drug classes, including diuretics, β -blockers, calcium-channel blockers, angiotensin converting-enzyme (ACE) inhibitors and angiotensin II type 1 receptors (AR1) blockers, reduces the incidence of cardiovascular complications. Over the past decade, clinical trials of blood pressure-lowering drugs shifted focus from placebocontrolled to actively controlled designs in hypertensive patients and from primary to secondary prevention in highrisk patients with or without hypertension. The research goal underlying many of the more recent trials was to prove that the new classes of antihypertensive drugs provide superior protection against cardiovascular complications, especially in patients with a previous history of cardiovascular disease, such as coronary heart disease or stroke. The aim of the present review was to summarize the main results of these studies in light of the overall evidence from clinical trials in hypertension and to investigate to what extent blood pressurelowering rather than specific ancillary properties might have contributed to the observed outcomes.
New vs. Old Antihypertensive Drugs
In consecutive quantitative overviews of the actively controlled outcome trials ( 5 − 7 ), we computed pooled estimates for the comparison of new antihypertensive drugs, such as calcium-channel blockers, ACE inhibitors, AR1 blockers and α -blockers, with conventional therapy consisting of diuretics and/or β -blockers. In 2003 ( 7 ), we reviewed 18 reports on 15 trials ( 8 − 25 ) , in which 120,574 patients had been randomized. Table 1 summarizes the characteristics of the trials comparing new antihypertensive drugs with conventional therapy, which were published in 2002 or later.
To compare new and old antihypertensive drugs, we computed pooled odds ratios from stratified 2 × 2 contingency tables. If Zelen's test of heterogeneity was significant, we used a random effects model.
Calcium-Channel Blockers vs. Conventional Therapy
For the comparison of calcium-channel blockers with conventional therapy, our last review ( 7 ) considered 9 trials ( 8 , 10 − 13 , 19 − 21 , 26 ) with 67,435 randomized patients. These trials were ALLHAT/Aml ( 21 ), CONVINCE ( 19 ) , ELSA ( 20 , 22 ) , INSIGHT ( 12 ) , MIDAS ( 8 ) , NICS ( 10 ), NORDIL ( 13 ), STOP2/CCBs ( 11 ) , and VHAS ( 26 ) . None of the outcomes considered in these analyses, including total and cardiovascular mortality, all cardiovascular events ( Fig. 1) , stroke ( Fig.  2 ), myocardial infarction (Fig. 3 ) or heart failure, showed a statistically significant level of heterogeneity among the trials ( 7 ) .
The pooled odds ratios expressing the possible benefit of calcium-channel blockers over old drugs were close to unity and non-significant for total mortality (0.98; 95% confidence interval CI, 0.92 − 1.03; p = 0.42), cardiovascular mortality (1.03; CI, 0.95 − 1.11; p = 0.51), all cardiovascular events (1.03; CI, 0.99 − 1.08; p = 0.15) and myocardial infarction (1.02; CI, 0.95 − 1.10; p = 0.61). Calcium-channel blockers provided slightly better protection against fatal and non-fatal stroke than old drugs (Fig. 2) . For the 9 trials combined ( 8 , 10 − 12 , 20 , 21 , 26 − 28 ) , the pooled odds ratio for stroke was 0.92 (CI, 0.84 − 1.01; p = 0.07). After exclusion of CON-VINCE ( 28 ) , a large trial based on verapamil, the odds ratio for stroke was 0.90 and reached significance (CI, 0.82 − 0.98; p = 0.02). For heart failure, calcium-channel blockers provided less protection than conventional therapy, regardless of whether (1.33; CI, 1.22 − 1.44; p < 0.0001) or not (1.33; CI, 1.22 −1.46; p< 0.0001) we incorporated the CONVINCE trial (28) in the pooled estimates.
A re-run of the analysis in December 2004 with coronary heart disease and stroke as the outcomes of interest confirmed the above results (7) . In addition to the 9 trials (8, 10−12, 20, 21, 26−28) previously reviewed, we also included INVEST (29) and SHELL (30) , but not AASK, because the published information on cause-specific cardiovascular complications was not sufficiently detailed (31) . The p-values for heterogeneity remained non-significant. Pooled estimates were 1.02 (CI, 0.96−1.09; p= 0.55) and 0.92 (CI, 0.85−0.99; p= 0.03) for coronary heart disease and stroke, respectively. After exclusion of the 2 verapamil-based trials (28, 29) , the common odds ratio for stroke was 0.90 (CI, 0.82−0.98; p= 0.02).
ACE Inhibitors vs. Conventional Therapy
Our 2003 review (7) considered 6 trials (9, 11, 16, 21, 23, 25) that compared ACE inhibitors with old drugs and that had a combined total of 47,519 randomized patients. These trials included: ALLHAT/Lis (21), ANBP2 (23) , CAPPP (9) , HYVET/AD (25) , STOP2/ACEIs (11) , and UKPDS/CA (16) . For total and cardiovascular mortality, stroke ( Fig. 2 ) and myocardial infarction (Fig. 3) , p-values indicating heterogeneity among these trials were non-significant. In contrast, for all cardiovascular events ( Fig. 1 ) and heart failure, heterogeneity was significant due to the ALLHAT findings (21) . Compared to those treated with chlorthalidone (21) , the ALLHAT patients given lisinopril had greater risks of stroke (1.15; CI, 1.02−1.30; p= 0.02), heart failure (1.19; CI, 1.07−1.31; p< 0.001), and hence combined cardiovascular disease (1.10; CI, 1.05−1.16; p< 0.001).
The pooled odds ratios expressing the possible benefit of ACE inhibitors over conventional therapy were close to unity and non-significant for total mortality (1.00; CI, 0.94−1.06; p= 0.89), cardiovascular mortality (1.02; CI, 0.94−1.11; p= 0.61), all cardiovascular events (1.03; CI, 0.94−1.12; p= 0.59), myocardial infarction (0.97; CI, 0.90−1.04; p= 0.39), and heart failure (1.04; CI, 0.89−1.22; p= 0.64). Compared to old drugs, ACE inhibitors gave slightly less protection against stroke with a pooled odds ratio of 1.10 (CI, 1.01−1.20; p= 0.03). A further review of the literature in December 2004 did not reveal new trials comparing ACE inhibitors to diuretics in addition to the 6 studies already analyzed in 2003 (7) . The AASK trial (31) incorporated a comparison of ramipril with metoprolol, but only provided aggregate cardiovascular outcomes and therefore could not be included.
AR1 Blockers vs. Conventional Therapy
The LIFE trial (Table 2 ) compared the efficacy of losartan and atenolol as first-line treatments in hypertensive patients with left ventricular hypertrophy (17, 18) . SCOPE (24) was set up as a double-blind placebo-controlled trial. However, open-label antihypertensive drugs, which mainly consisted of diuretics, β-blockers, or both classes of old drugs, were added to the double-blind study medication in a considerably greater proportion of the patients randomized to placebo than in those allocated candesartan. There was no statistically significant heterogeneity between the results of these 2 trials (7). The levels of protection conferred against total mortality, cardiovascular death and myocardial infarction were similar between the control groups and the groups treated with an AR1 blocker. The pooled odds ratios were 0. 91 
New vs. Old Antihypertensive Drugs
Our 2003 review demonstrated that across 15 trials (8−21, 23−25) , outcomes for total and cardiovascular mortality, and myocardial infarction (Fig. 3) were consistent. The pooled odds ratios did not deviate from unity, averaging 0.98 (CI, 0.94−1.02; p= 0.38), 1.00 (CI, 0.95−1.07; p= 0.88) and 1.00 (CI, 0.95−1.06; p= 0.87), respectively. In contrast, for all cardiovascular events (Fig. 1) , stroke ( Fig. 2 ) and heart failure, there was significant heterogeneity (p< 0.001) across the 15 trials (8−21, 23−25) , which was largely due to the ALLHAT results (14, 21, 32) . First-line therapy with a diuretic provided more benefit than amlodipine and doxazosin with regard to heart failure and more benefit than lisinopril and doxazosin in the prevention of stroke. For all cardiovascular events and stroke, the overall odds ratios were 1.01 (CI, 0.95−1.09, p= 0.69) and 0.98 (CI, 0.88−1.08; p= 0.64), respectively. Compared to conventional therapy, new drugs offered less protection against heart failure with a pooled odds ratio of 1.23 (CI, 1.03−1.47; p= 0.02).
Calcium-Channel Blockers vs.

AR1 Blockers
Two secondary prevention trials ( The VALUE investigators undertook a double-blind clinical trial to test the hypothesis that, for the same degree of blood pressure lowering, inhibition of the renin system at the level of the AR1 would be more effective in the prevention of cardiac morbidity and mortality than calcium-channel blockade (36−40) . Across 943 centers and 31 countries (36, 37, 39) , 15,245 high-risk patients were randomized to receive antihypertensive treatment based on either valsartan (80−160 mg/ day) or amlodipine (5−10 mg/day) and followed-up for a median of 4.2 years. The VALUE investigators assumed that the primary endpoint, a composite of fatal and non-fatal cardiac endpoints, would run at a rate of 25 events per 1,000 patient-years (37) . Within less than 5 years, the number of cardiac endpoints exceeded the projected number of 1,450 by 149. Cardiac endpoints occurred at similar rates in the two treatment groups, because the incidence of myocardial infarction was lower (0.84; 0.72−0.98; p= 0.02) on amlodipine than valsartan, whereas on amlodipine the risk of heart failure tended to be increased (1.12; 0.97−1.30; p= 0.12). The incidence of fatal and non-fatal stroke was lower (0.87; 0.74− 1.02; p= 0.08) on amlodipine than valsartan. A unique feature of VALUE was the comprehensive assessment of cardiovascular risk at baseline (37) and the implementation of a strategy to stabilize risk at a high level across 6 strata based on gender and age (50−59, 60−69 and ≥ 70 years). 
Placebo-Controlled Secondary Prevention Trials
Several secondary prevention trials have compared the levels of cardiovascular protection conferred by conventional antihypertensive therapy and the combination of conventional antihypertensive therapy and new antihypertensive agents. In 5 trials with 12,342 randomized patients (Table 2) , the experimental agent was a dihydropyridine calcium-channel blocker: amlodipine in CAMELOT/Aml (41), PREVENT (42, 43) , and IDNT2 (33−35); nifedipine GITS (gastro-intestinal therapeutic system) in ACTION (44, 45) ; and nisoldipine in NICOLE (46, 47) . In 9 trials with 43,227 randomized patients ( (57); and trandolapril in PEACE (58) . All patients randomized in these trials were high risk patients with a history of cardiovascular disease and/ or diabetes mellitus (54−56), nephropathy (33, 35) , documented coronary heart disease (41, 43, 44, 46−49, 57, 58) or a previous cerebrovascular accident (51, 59) . All (33, 41, 44, 49, 54, 55, 58) but 5 (43, 46, 48, 51, 57) of the placebo-controlled secondary prevention trials had a composite primary endpoint (Tables 2 and 3 ). In 3 trials (41), the composite endpoint included coronary (41, 58) or peripheral (44) revascularization procedures. In 4 trials the primary end- AR1, angiotensin type 1 receptor; A, refractory or hospitalized angina pectoris; ACM, all-cause mortality; BP, blood pressure; CAA, atheromatosis of the carotid artery; COA, coronary atheromatosis; CAR, resuscitated cardiac arrest; CHD, coronary heart disease; CR, coronary revascularization; CVM, cardiovascular mortality; ESRD, end-stage renal disease; HF, heart failure; MI, non-fatal myocardial infarction; PAD, peripheral arterial disease; PR, peripheral revascularization; S, non-fatal stroke; SCrt(2×), doubling of the serum creatinine concentration. Acronyms of trials are explained in the Appendix. *Blood pressure at entry was always measured on antihypertensive medication in previously treated patients. †
Negative values indicate tighter blood pressure control in the reference group. ‡ Significant difference in achieved blood pressure between randomised groups. §
The blood pressure differences between the amlodipine and irbesartan groups were non-significant. point consisted only of the rate of change of carotid (43, 48) or coronary (46, 57) atherosclerosis, and hard endpoints, such as stroke or myocardial infarction, were only secondary outcomes. The use of composite endpoints with varying definitions (Tables 2 and 3 ) and the wide range of secondary endpoints made obtaining pooled estimates for overall treatment effects difficult. CAMELOT (41) and PEACE (58) only reported non-fatal cases of myocardial infarction. Stroke included transient ischemic attack in CAMELOT (41) and was limited to non-fatal events in PART2 (57) .
Among the 5 trials of dihydropyridine calcium-channel blockers (35, 41, 43, 44, 47) , there was no heterogeneity in the results with regard to stroke (p= 0.81), myocardial infarction (p= 0.16) and the composite of all cardiovascular events, which also included procedures and revascularization (p= 0.52). The pooled odds ratios were: 0.71 (CI, 0.55−0.92; p= 0.0015), 0.97 (CI, 0.83−1.13; p= 0.70), and 0.78 (CI, 0.72−0.85; p< 0.0001), respectively. When the analysis was limited to the 3 trials involving amlodipine as the experimental agent (35, 41, 43) , these pooled estimates were 0.60 (CI, 0.36−0.97; p= 0.038) for stroke, 0.69 (CI, 0.49−0.97; p= 0.033) for myocardial infarction, and 0.73 (CI, 0.62−0.85; p= 0.0001) for cardiovascular events.
Among the placebo-controlled trials of ACE inhibitors (41, 48, 49, 51, 54, 55, 57, 58) , there was significant heterogeneity (p≤ 0.001) in the results for all cardiovascular endpoints and stroke, but not for myocardial infarction (p= 0.25). In these analyses, the 2 strata in the PROGRESS trial were treated In a factorial design, the patients were also randomized to simvastatin or placebo.
separately (monotherapy with perindopril vs. placebo; and perindopril plus indapamide vs. matching placebos). Cardiovascular events included revascularization procedures in CAMELOT (41) and total mortality in SCAT (48), but not in the other trials (49, 51, 54, 55, 57, 58) . Across the available studies (41, 48, 49, 51, 54, 55, 57, 58) , the pooled odds ratios for ACE inhibition vs. placebo were highly significant (p< 0.0001), amounting to 0.81 (CI, 0.77−0.86) for cardiovascular events, 0.77 (CI, 0.69−0.84) for stroke, and 0.80 (CI, 0.73−0.86) for myocardial infarction. In sensitivity analyses, we excluded EUROPA (49) and PROGRESS/Per (51), 2 trials of perindopril given in monotherapy, and DIABHYCAR (54) , in which the difference in systolic blood pressure (SBP) between the ramipril and placebo group was only 1.5 mmHg. These exclusions removed the heterogeneity for stroke (p= 0.11) and decreased the common odds ratio for stroke to 0.63 (CI, 0.56−0.72; p< 0.0001).
In addition to the endpoints reviewed above, several secondary prevention trials, including AASK (31, 60) , ABCD (61−65), BENEDICT (66, 67) , CALM (68), HOPE (56), IRMA2 (69), REIN (70), RENAAL (71), IDNT2 (33−35) and a number of earlier published smaller trials (72), demonstrated that ACE inhibitors, AR1 blockers or their combination reduce the progression of renal impairment in patients with microalbuminuria or proteinuria in the presence or absence of diabetes mellitus.
Role of Blood Pressure Reduction
In 2001 (5, 6), we computed the relation between the odds ratios of experimental vs. reference treatment and the corresponding baseline-corrected differences in SBP between randomized groups. Our meta-regression analysis (6) involved 30 trials including 149,407 randomized patients: 9 actively controlled trials (MIDAS (8) , CAPPP (9, 73) , NICS (10), STOP2 (11), INSIGHT (12, 74) , NORDIL (13), ALLHAT/ Dox (14) , VHAS (26) , and UKPDS (16, 75) ); the HOT trial (76) , which investigated 3 levels of diastolic blood pressure (96)). Seven studies were excluded for the following reasons: fewer than 100 patients had been randomized (97−99), follow-up was less than 2 years (100, 101), insufficient information was published on achieved SBP (HDFP (102, 103) ) or non-fatal outcomes (CASTEL (104)), and/or randomization took place between usual and referred care (CASTEL (104) and HDFP (102, 103) ).
Fig. 4. Odds ratios for cardiovascular mortality (left panel) and all cardiovascular events (right panel) in relation to corresponding differences in systolic blood pressure (SBP
As previously reported (5, 6, 105) , the meta-regression line relating the odds ratios for cardiovascular mortality (Fig. 4 , left panel) to the corresponding within-trial differences in SBP was linear. For all cardiovascular events (Fig. 4 , right panel), stroke (Fig. 5, left panel) and myocardial infarction (Fig. 5, right panel) , these relations were curvilinear. For these fatal and non-fatal outcomes combined, there was no further benefit if the within-trial differences in SBP exceeded 15 mmHg. Because, in our meta-regression analysis (5, 6, 105) , the odds ratios respected the randomization, and because within each trial patients had similar characteristics at entry, adjustment for the baseline SBP did not materially alter the position of the regression lines.
In our first reviews (5, 6, 105) , we compared observed odds ratios and those that could be predicted by meta-regression from the baseline-adjusted differences in achieved SBP between randomized groups. Among 6 trials of new vs. old drugs (ALLHAT/Dox (14) , CAPPP (9, 73) , MIDAS (8), NICS (10), NORDIL (13) , and VHAS (26)) and 4 placebocontrolled trials (HOPE (55, 56) , PART2 (57), PROGRESS (51, 59, 85) , and SCAT (48)), the gradients in achieved SBP ranged from 1.8 mmHg (8) to 12.0 mmHg (51) . Differences between observed and predicted odds ratios were not significant apart from those for stroke in NORDIL (13) and PROGRESS/Per (51, 59, 85) . In the former study (13) , the risk was lower in patients on diltiazem than on old drugs despite the fact that the SBP was 3.1 mmHg higher on the calcium-channel blocker (Table 4 ). In PROGRESS/Per (51), monotherapy with perindopril reduced SBP by 5.0 mmHg compared to placebo, but had no influence on stroke recurrence or the incidence of all cardiovascular events.
In our 2003 update (7), we considered 7 additional studies allowing comparison of outcomes on new vs. old drugs (ALL-HAT (21), ANBP2 (23), CONVINCE (19) , ELSA (20, 22) , HYVET/AD (25), LIFE (17, 18, 106, 107) , and SCOPE (24, 108, 109) ). Taking conventional therapy with diuretics and β-blockers as a reference, the achieved SBP was higher on amlodipine in ALLHAT/Aml (1.1 mmHg), on lisinopril in ALLHAT/Lis (2.3 mmHg), and on ACE inhibitors in ANBP2 (2.0 mmHg). In contrast, in LIFE/All (1.1 mmHg) and LIFE/ DM (3.0 mmHg) as well as in SCOPE (3.2 mmHg), SBP was significantly higher in the reference group on conventional therapy than in the patients allocated losartan or candesartan, respectively. In general, there were no significant differences between the observed and predicted odds ratios in the reviewed outcomes in any of these trials (7). Myocardial infarction (p= 0.02) and consequently all cardiovascular events (p= 0.05) in the ANBP2 trial (23) constituted the only significant exceptions (Table 4 ). In the ANBP2 patients randomized to the ACE inhibition group, SBP was on average 2.0 mmHg higher than in those allocated to receive diuretic treatment (23) . The predicted odds ratios therefore tended to be higher than unity, whereas for all cardiovascular events (1.15 vs. 0.90) and myocardial infarction (1.08 vs. 0.70) the opposite was observed. For myocardial infarction (Table 4) , borderline differences between predicted vs. observed odds ratios in favor of ACE inhibition were also observed in ALL-HAT/Lis, both in all patients (1.14 vs. 0.98; p= 0.08) and in those aged 65 years or more (1.20 vs. 1.01; p= 0.08).
In our 2003 update (7), we also reviewed 2 trials that compared tight to conventional blood pressure control (AASK (31, 60, 110) and ABCD/NT (65)) and 5 placebo-controlled designs (DIABHYCAR (52−54), HYVET/BP (25), IDNT2 (33−35), NICOLE (46, 47) , and PREVENT (42, 43) ). For these 7 trials (25, 35, 43, 47, 54, 60, 65) , observed and predicted odds ratios were similar with the exception of cardiovascular mortality in HYVET/BP (Table 4) . In spite of a 22.5 mmHg lower SBP in the patients randomized to active treatment than in those left untreated, cardiovascular mortality did not decrease (observed vs. predicted odds ratios, 1.19 vs. 0.55; p= 0.02). For all cardiovascular events in AASK (60), the The table includes specific outcomes, for which the significance of the difference between observed vs. predicted odds ratios was significant or borderline significant. Endpoints tested included cardiovascular mortality (CVM), cardiovascular events (CVE) consisting of CVM, fatal and non-fatal stroke, and fatal and non-fatal myocardial infarction (MI), as available in 44 trials. *ΔSBP is the difference in systolic blood pressure between randomized groups in mmHg, negative values indicating tighter blood pressure on control than on reference treatment. † Observed odds ratios with exact 95% confidence intervals were calculated from the number of events (control/experimental) and the number of patients (Table 2) observed odds ratios tended to be higher than predicted (0.88 vs. 0.60; p= 0.07 (60) (39, 40) , with regard to myocardial infarction, the observed outcome on valsartan was worse than predicted (1.19 vs. 0.98; p= 0.03), while that of amlodipine-based treatment was better than predicted from the gradient in the achieved SBP (0.84 vs. 1.02; p= 0.03; Table 4 ). Figure 6 provides detailed information on the observed and predicted odds ratios for stroke in 5 placebo-controlled secondary prevention studies of dihydropyridine calcium-channel blockers (35, 41, 43, 44, 47) and for 8 placebo-controlled secondary intervention trials of ACE inhibitors (41, 48, 49, 51, 54, 55, 57, 58) . Figure 7 gives similar information for myocardial infarction.
Interpretation of the Evidence
The main finding of our updated overview was that, by and large, reduction in SBP explained the cardiovascular outcomes in the recently published, actively controlled trials in hypertensive patients and in the placebo-controlled secondary prevention trials. On balance, the evidence suggested that
Fig. 6. Observed vs. predicted odds ratios for stroke in 5 placebo-controlled secondary prevention trials of dihydropyridine calcium-channel blockers (DHP, top) and 8 placebo-controlled secondary prevention trials of ACE inhibitors (ACEI, bottom). Predicted odds ratios were derived by meta-regression (Fig. 5). For each trial, the total number of patients analyzed and the percent of patients who experienced an event are given. p-values are for the comparison between observed and predicted odds ratios. Acronyms of trials are defined in the Appendix. Ind., indapamide.
dihydropyridine calcium-channel blockers might offer a slight but selective benefit in the prevention of stroke and inhibitors of the renin-angiotensin system in the prevention of heart failure. For prevention of myocardial infarction, the published results were more equivocal, because of the benefit of amlodipine over placebo (35) or valsartan (39, 40) in 2 trials, whereas other placebo-controlled trials of calcium-channel blockers (44, 47) or ACE inhibitors (41, 54, 58) did not substantiate the expected advantage with regard to cardiac outcomes.
Prevention of Stroke
In 2001 (5), we had already noted that calcium-channel blockers, compared to conventional therapy with diuretics and/or β-blockers, gave 13.5% (p= 0.03) greater reduction in the risk of stroke. In our 2003 review (7), we added the ALLHAT/ Aml (21), CONVINCE (19) and ELSA (20, 22) trials, and in our present overview we further added INVEST (29) and SHELL (30) (Fig. 5) (31, 60, 110, 114) , ALLHAT/Aml (21), CONVINCE (19) , and ELSA (20, 22) , but not INVEST (29) . In these consecutive overviews, the estimates of the benefit of calcium-channel blockers over old drugs in the prevention of stroke were 13.0% (112) and 7.0% (113), respectively. All calcium-channel blockers bind to a specific receptor domain situated on the α1-subunit of the L type calcium channel (115) , but amlodipine also binds to diltiazem receptors (115) . These pharmacologic characteristics, but more importantly, the low probability of heterogeneity among the trials involving dihydropyridines and diltiazem (p= 0.80), provided a rationale for a sensitivity analysis combining these 2 subclasses of calcium-channel blockers. After exclusion of the 2 verapamilbased trials (28, 29) , we found a 10.0% (p= 0.02) better prevention of stroke on calcium-channel blockers than old drugs.
. Observed vs. predicted odds ratios for myocardial infarction in 5 placebo-controlled secondary prevention trials of dihydropyridine calcium-channel blockers (DHP, top) and 8 placebo-controlled secondary prevention trials of ACE inhibitors (ACEI, bottom). Predicted odds ratios were derived by meta-regression
In 2001 (5), we reviewed 3 trials comparing ACE inhibitors to conventional therapy (9, 11, 16) , which together included 16,551 randomized patients. Both treatment modalities gave similar protection against cerebrovascular accidents (5) . In the present analysis, the number of relevant trials increased to 5 (9, 11, 16, 21, 23 ) and the number of randomized patients rose to 46,553. In contrast to our former findings (5), ACE inhibitors gave 10.2% less reduction in the risk of stroke than the old antihypertensive drugs. These results are in line with the secondary prevention trials in patients with a history of cerebrovascular disease, which tested inhibitors of the renin system (51, 116) or indapamide (84) against placebo. Neither atenolol in TEST (116) nor perindopril in the monotherapy arm of the PROGRESS trial (51) reduced the incidence of stroke recurrence, whereas in the Chinese PATS trial (84) , for a similar reduction in SBP (5.0 mmHg), indapamide decreased recurrent stroke by 29%. In the EUROPA trial (49) , in patients with coronary heart disease, perindopril given on top of the usual therapy did no better than placebo for the primary prevention of stroke.
In 2 trials (23, 24) , AR1 blockers resulted in 24.4% better stroke prevention than did the old drugs, whereas the opposite trend was observed in the doxazosin arm of the ALLHAT trial -17.5%, p= 0.04). A comprehensive overview of observational cohort studies recently highlighted the fact that, throughout middle and old age, blood pressure is strongly and directly related to stroke mortality (1) . Hypertension is the most consistent and powerful predictor of stroke (1, 117) and is involved in nearly 70% of strokes (117) . It is therefore impossible to interpret the stroke results of our overview without taking into account the within-trial differences in achieved SBP (see below).
Prevention of Myocardial Infarction
We reported in 2001 (5, 6) that calcium-channel blockers, compared to diuretics and β-blockers, gave 19.2% less reduction of the risk of myocardial infarction (5) . The corresponding pooled estimate reported by the Blood Pressure-Lowering Treatment Trialists' Collaboration was 12.0% (112) . In the present update, the shortfall of calcium-channel blockers relative to conventional therapy disappeared in part as a result of the positive trend in favor of verapamil in CONVINCE (0.81; CI, 0.64−1.02; p= 0.08 (28) ) and the similar coronary outcomes on amlodipine and chlorthalidone in ALLHAT (0.99; CI, 0.90−1.08; p= 0.79 (21)) and on verapamil and atenolol in INVEST (1.03; CI, 0.90−1.18; p= 0.68 (29) ). Furthermore, in our previous (5, 6) as well as our current analysis, ACE inhibitors and old drugs performed equally well in the prevention of myocardial infarction. ANBP2 (23, 118) was the only actively controlled trial of ACE inhibitors, which showed a borderline significant benefit over conventional therapy in the prevention of fatal and non-fatal myocardial infarction (0.70; CI, 0.45−1.00; p= 0.048). Thus, in the actively controlled trials, new drugs and conventional therapy prevented coronary complications to the same extent. This conclusion is supported by the observation that, for myocardial infarction, none of the p-values for heterogeneity reached the level of statistical significance.
Among 8 placebo-controlled secondary prevention studies (41, 48, 49, 51, 54, 55, 57, 58) , ACE inhibitors reduced the risk of myocardial infarction by 20%. However, among individual trials, ACE inhibition did not lead to significantly fewer myocardial infarcts in CAMELOT/En (0.55; CI, 0.26− 1.15; p= 0.11 (41)), DIABHYCAR (0.79; CI, 0.57−1.10; p= 0.16 (54) ) and PEACE (1.00; CI, 0.83−1.20; p> 0.99 (58) ). Some investigators (58) have attributed these null results to the high frequency of background therapy with lipid-lowering drugs and anti-platelet agents. However, this explanation is unlikely because the use of such drugs was similarly high in trials that demonstrated a difference in the risk of myocardial infarction, such as EUROPA (49), or VALUE (39, 40) . More likely explanations are that either the sample size was too small to achieve significant results (41) or that the difference in SBP between randomized groups was relatively small (54, 58) .
Among 5 placebo-controlled secondary prevention studies (35, 41, 43, 44, 47) , dihydropyridine calcium-channel blockers did not significantly decrease the risk of myocardial infarction. However, across the 3 trials in which amlodipine was the experimental drug, i.e., CAMELOT/Aml (41), IDNT2 (35) , and PREVENT (43), amlodipine achieved a 31% higher reduction in the risk of myocardial infarction (p= 0.033) than placebo. These results are in line with those of the VALUE trial (39, 40) , in which amlodipine showed a 16% greater benefit than valsartan (p= 0.02). These observations raise the question of whether dihydropyridine calciumchannel blockers behave as a single class for prevention of myocardial infarction. Indeed, among individual trials, point estimates tended to be higher than unity or were equal to unity for nisoldipine vs. enalapril in the revised ABCD/HT results (44)). Differences between randomized groups in achieved SBP were small and non-significant in ABCD/HT (61) and INSIGHT (12) , but favored the calcium-channel blocker in NICOLE (9.1 mmHg (47)), JMIC-B (2.0 mmHg (119)), and ACTION (6.0 mmHg (44)). Why amlodipine apparently prevented myocardial infarction more efficiently than long-acting nifedipine or nisoldipine remains to be elucidated. Several mechanisms might be involved, including the long duration of action of amlodipine, the increase in heart rate observed on nifedipine (44), the possible influence of subclinical gastrointestinal conditions on the absorption of nifedipine from a slow-release formulation, or differences between the trials in the characteristics of the randomized patients.
The results of the blood pressure-lowering limb of ASCOT (120), due to be published in 2005, might shed more light on the prevention of myocardial infarction. In a 2 × 2 factorial design (120, 121), 19,342 hypertensive patients were randomized to receive amlodipine singly or in combination with perindopril or atenolol singly or in combination with bendrofluazide (open-label treatment with blinded endpoint validation), while a subgroup of 10,305 patients received double-blind treatment with either atorvastatin or placebo. The primary endpoint was the combination of death from coronary heart disease and non-fatal myocardial infarction (120, 121) . Because of benefit in terms of outcome, the atorvastatin and amlodipine arms were stopped in September 2002 (121) and November 2004, respectively. The achieved blood pressure was lower on the new than on the old antihypertensive drugs. An interaction between blood pressure and lipid lowering might therefore have contributed to the immediate separation of the Kaplan-Meier estimates in the lipid trial (121) .
Prevention of Heart Failure
The risk of heart failure was higher on calcium-channel blockers than on conventional therapy without heterogeneity among the trials. In individual studies, the risk of heart failure was significantly increased on nifedipine GITS in INSIGHT (2.18; CI, 1.06−2.18; p= 0.03 (12)), on amlodipine in ALL-HAT (1.38; CI, 1.25−1.50; p< 0.001 (21)), and on verapamil in CONVINCE (odds ratio 1.30; CI, 1.00−1.69; p= 0.05 (19) ). Calcium-channel blockers reduce left ventricular afterload. However, neuro-endocrine activation in response to arterial vasodilatation, as exemplified by the increase in heart rate induced by nifedipine in the ACTION trial (44) , as well as the direct negative inotropic action on the myocardium, may elicit heart failure in predisposed patients (122) . Nevertheless, on top of diuretics and/or ACE inhibitors, long-acting dihydropyridines (123, 124) , diltiazem (125) and verapamil (126) can be used in patients with left ventricular dysfunction to lower blood pressure or to treat angina pectoris. The reduction of heart failure on nifedipine GITS vs. placebo in ACTION (0.71; CI, 0.54−0.94; p= 0.015 (44)) was unexpected, but may have been due to the 6.0 mmHg lower SBP in the patients on nifedipine or to unbalanced prescription of background medications in favor of the actively treated patients. The ACTION report (44) , similarly to several other studies (54, 55, 58) , did not provide any information on concomitant medications after randomization.
Among the trials of new vs. old drugs (7), all newer agents on average performed 23.1% worse in the prevention of heart failure than conventional therapy. This is not surprising, because both diuretics and β-blockers belong to the standard of care (127) . The same is true for ACE inhibitors given on top of digitalis and diuretics. AR1 blockers, perhaps with the exception of candesartan titrated up to 32 mg daily (128− 131) , are only indicated as alternatives to ACE inhibitors when class-specific side-effects, such as cough, occur (127, 132−134) . Two trials of the combination of ACE inhibitors and AR1 blockers in patients with heart failure reported contradictory results (130, 135) .
The higher risk of heart failure on lisinopril in ALLHAT (1.19; CI, 1.07−1.31; p< 0.001 (21)) is counterintuitive, whereas the results of the ALLHAT doxazosin arm (1.80; CI, 1.61−2.02; p< 0.001 (14, 32) ) were in line with previous studies (136) . In trials of ACE inhibitors in patients with heart failure (127) or high cardiovascular risk (51, 55) , these agents were always combined with diuretics. In contrast to current guidelines (3, 137) , in therapy-resistant ALLHAT patients, lisinopril had to be used in combination with sympatholytic agents and/or hydralazine before diuretics could be added (21) . Furthermore, heart failure in ALLHAT was only a component of a secondary endpoint, which did not lead to an increase in cardiovascular (21) or total (14, 21) mortality. At randomization, 90.2% of the ALLHAT patients were already on antihypertensive drugs, diuretics in most cases. Thus, the patients allocated to receive amlodipine, lisinopril or doxazosin were at risk of rapidly losing the protection conferred by their previous diuretic treatment, whereas in those of the chlorthalidone group the volume-dependent signs and symptoms of heart failure remained suppressed. These design features of ALLHAT likely explain why the Kaplan-Meier estimates for heart failure separated immediately after randomization (14, 21, 32) . Because of the weight of ALLHAT in our overview, pooled estimates including this trial must be cautiously interpreted.
In the main analysis of the VALUE trial (39), the risk of heart failure was slightly less on valsartan than amlodipine (0.89; CI, 0.77−1.03; p= 0.12). This trend reached borderline significance in 2 post-hoc analyses (39, 40) . First, the VALUE investigators artificially subdivided the follow-up period into consecutive intervals characterized by progressively decreasing between-group differences in SBP (39) . In the interval from 36 to 48 months the risk was 0.69 (CI, 0.51− 0.94). However, these time-interval-specific analyses were biased for all periods but the first (0−3 months), because event rates in each sequential period were conditional on those occurring earlier (39, 40) . Patients continuing to each subsequent period were therefore unbalanced with regard to risk and randomization. Second, in an accompanying paper (40) , the VALUE consortium performed serial median matching using the SBP level at 6 months and found that the risk of heart failure on valsartan vs. amlodipine was 0.81 (CI, 0.66− 0.99; p= 0.04). This matched-pair approach (40) accounted for the attained SBP (within 2 mmHg) and other cardiovascular risk factors, but excluded 5,233 patients (34.3%) whose SBP was too high on valsartan or too low on amlodipine to allow matching.
Role of Blood Pressure Reduction
Until the turn of the millennium, the consensus interpretation of the evidence produced by the outcome trials in hypertensive patients (8−16, 27, 28, 48, 51, 57, 75−88, 90−96, 106, 138) was that blood pressure is a risk factor amenable to intervention, with lower levels entailing fewer complications. However, the HOPE trial (55, 56) gave rise to the hypothesis that ACE inhibitors might reduce cardiovascular complications beyond blood pressure control. Subsequently, trials of AR1 blockers in hypertensive patients with renal failure (33, 69, 71) or left ventricular hypertrophy (17, 18) as well as several secondary prevention trials of ACE inhibitors (35, 49, 54, 58) or AR1 blockers (39) sought to reinforce this hypothesis.
Our previous meta-regression analyses (5−7) along with the present overview in total considered 45 trials (8−14, 16− 21, 23−25, 27, 29, 30, 32−35, 39, 40, 43, 44, 46−48, 51, 54− 57, 59, 71, 74−77, 79−84, 86−96, 109, 119) . Several of these trials involved multiple comparisons of various active drugs with placebo or with each other. From each trial and for each comparison, we tried to extract information on cardiovascular mortality, cardiovascular morbidity, stroke and myocardial infarction. A substantial number of the reviewed trials (18− 21, 23−25, 29, 30, 35, 39, 41, 43, 44, 47, 49, 51, 54, 58, 60, 65) announced their results after 2001, when we had first published our meta-regression models (5) . To standardize our analysis, we did not use adjusted relative risks as published in many articles. Instead, we recalculated the observed odds ratios from the number of events and the number of patients per group randomized in each trial by use of 2 × 2 contingency tables (5) . Across all reviewed trials and endpoints, only in 14 instances did we find a significant or borderline significant difference between observed and predicted odds ratios. These findings underscore that the outcome results of most trials in patients with hypertension or high cardiovascular risk should be attributed to the within-trial differences in SBP. This point of view is also in line with the evidence from observational, prospective studies. Indeed, in middle-aged and older patients, SBP is the prevailing blood pressure component with regard to cardiovascular prognosis (139, 140) . In a quantitative overview involving one million subjects, the Prospective Studies Collaboration demonstrated that small gradients in blood pressure similar to those observed in recent trials might account for substantial differences in cardiovascular outcomes (1) .
For myocardial infarction (0.70 vs. 1.08) in the ANBP2 trial (23) , and hence for all cardiovascular events (0.90 vs. 1.15), the odds ratios for therapy with ACE inhibitors vs. conventional therapy were significantly lower than those predicted by the achieved SBP, which was 2.0 mmHg higher in the patients on ACE inhibitors. Similar trends were also observed for myocardial infarction in the lisinopril arm of the ALLHAT trial (21) , both in all patients (0.98 vs. 1.14) and in those aged 65 years or more (1.01 vs. 1.20), whose SBP was 2.3 and 3.0 mmHg higher, respectively, than in the corresponding controls randomized to receive chlorthalidone. Thus, if one considers the achieved SBP, ACE inhibitors in Caucasian hypertensive patients seem to offer a slightly greater protection against coronary complications than conventional therapy. These findings are in line with the secondary prevention trials in patients with acute myocardial infarction (141, 142) . CAMELOT (41) and PEACE (58) only reported the incidence of non-fatal myocardial infarction, which in the context of the endpoint definitions used in the present overview does not facilitate the interpretation in relation to blood pressure.
The achieved SBP levels and associated stroke rates in the lisinopril arm of the ALLHAT trial (21) corroborated the concept that older and black patients usually have a low-renin volume-expanded type of hypertension, which responds better to initial treatment with diuretics or calcium-channel blockers (143−146) . In 2 trials comparing AR1 blockers (18, 24) with conventional therapy, the realization of lower SBP explained the better outcomes on losartan (17, 18) or candesartan (147) . Both trials had a double-blind design, but they were also characterized by the more frequent discontinuation of the double-blind study medication in the control group (18, 147) and the more frequent use of open-label drugs either in the experimental (18) or in the control (147) group. The systolic gradient was larger in SCOPE (147) than in LIFE (17, 18) , but the p-value for heterogeneity in the stroke outcomes between these 2 trials was non-significant. Thus, as discussed elsewhere (148), our present findings are at variance with the LIFE investigators' interpretation that claimed benefit beyond blood pressure control for losartan vs. atenolol (17, 18) . To what extent unopposed stimulation of type 2 angiotensin II receptors in the brain contributes to the divergent stroke outcomes on ACE inhibitors and AR1 receptor blockers relative to conventional therapy remains to be elucidated (149) .
Two instances in which there was a significant deviation between observed and predicted odds ratios highlight the need for further research. First, in the pilot run of the HYVET trial (25) , active treatment compared to no intervention low-ered SBP by 22.5 mmHg, but did not reduce cardiovascular mortality. The observed and predicted odds ratios were 1.19 vs. 0.55, respectively. Second, in the AASK trial (31, 60) , intensive blood pressure lowering compared to conventional care led to a 16.0 mmHg difference in SBP with less reduction in the cardiovascular event rate than expected (odds ratios, 0.88 vs. 0.60).
We did not compute a meta-regression line for heart failure, because among the 30 trials in our 2001 overview (5) only 13 reported on this endpoint and because the criteria for its diagnosis were not standardized across trials. In their 2003 report (113) , the Blood Pressure Lowering Treatment Trialists' Collaboration observed that for every outcome other than heart failure, the differences between randomized groups in cardiovascular outcomes were directly related to the achieved SBP. However, the lack of association for heart failure was mainly due to 4 trials, i.e., IDNT2 (33−35), NICOLE (46, 47) , PRE-VENT (42, 43) and Syst-Eur (81−83), which compared calcium-channel blockers to placebo. The question remains whether from a clinical point of view the pooled results of one primary prevention trial in older patients with isolated systolic hypertension (81) and of 3 secondary prevention studies in diabetic patients with renal dysfunction (35) or in high-risk patients with coronary heart disease (43, 47) can be usefully interpreted. Indeed, there are substantial differences in the pathophysiologic mechanisms causing left ventricular failure in such heterogeneous patient groups (150, 151) .
Conclusions
Most trials published over the past decade have enrolled primarily middle-aged and older patients of male sex at high cardiovascular risk, who had previous complications, associated diseases, or both. To what extent their findings can be reasonably extrapolated to younger and female patients in a routine clinical setting remains a matter of concern (152) .
The hypothesis that new antihypertensive drugs, such as calcium-channel blockers, α-blockers, ACE inhibitors or AR1 blockers, might influence cardiovascular prognosis over and beyond their antihypertensive effect remains unproven. In the primary and secondary prevention trials of blood pressure-lowering drugs, the achieved SBP was the major determinant of cardiovascular outcome. This observation is in keeping with the recent findings in Syst-Eur (153) and VALUE (39, 40) , which highlighted that immediate blood pressure lowering and early blood pressure control are key determinants of cardiovascular prognosis. Although a number of secondary prevention trials included normotensive patients, the level to which blood pressure must be lowered to achieve maximal benefit remains to be clarified.
The relevance of achieved blood pressure for cardiovascular prognosis must be gauged in terms of the poor control rates of SBP in the population at large (154) as well as in primary care (155) . If blood pressure is the major determinant of prognosis, the inescapable inference is that antihypertensive therapy should be individualized and initiated with the drug class that is most likely to be effective in each individual patient, taking into account his overall risk profile and comorbid conditions (3). In over 60% of patients, optimization of treatment at acceptable levels of tolerance requires rotation through and combination of several drug classes. The blood pressure-lowering activities of ACE inhibitors and β-blockers are additive to those of thiazides and calcium-channel blockers and vice-versa (145, 146) . Patients younger than 50 years may be started on ACE inhibitors or β-blockers and switched to combination therapy with either thiazides or calcium-channel blockers if blood pressure remains uncontrolled, whereas older patients may proceed in the reverse order (145, 146) . Because most patients need combination therapy to achieve blood pressure control, the debate which drug class is best suited to start antihypertensive treatment is largely elusive. (102, 103) ; HOPE, Heart Outcomes Prevention Evaluation study (55, 56) (42, 43) ; PROGRESS, Perindopril PrOtection aGainst Recurrent Stroke Study (51, 59, 85) ; PROGRESS/Com, Perindopril PrOtection aGainst Recurrent Stroke Study (51, 59, 85) ⎯group on combined therapy); PROGRESS/Per, Perindopril PrOtection aGainst Recurrent Stroke Study (51, 59, 85) (26) 
